aTYR PHARMA (ATYR) Gains from Investment Securities (2014 - 2015)
aTYR PHARMA's (ATYR) quarterly Gains from Investment Securities came in at $48000.0 in Q2 2015, down 12.73% YoY from $55000.0 in Q2 2014, and up 162.34% on a QoQ basis from -$77000.0 in Q1 2015.
aTYR PHARMA (ATYR) Gains from Investment Securities (2014 - 2015) Analysis & Trends
aTYR PHARMA (ATYR) has 2 years of Gains from Investment Securities data on file, last reported at $48000.0 in Q2 2015.
- Quarterly Gains from Investment Securities fell 12.73% year-over-year to $48000.0 in Q2 2015, while the trailing twelve-month figure through Dec 2015 was -$29000.0 (up 19.44% YoY) and the FY2015 annual result came in at -$29000.0, up 19.44% from the prior year.
- Gains from Investment Securities rose to $48000.0 in Q2 2015, from -$77000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $128000.0 in Q3 2014 to a low of -$249000.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | 48,000.00 |
| Jun 30, 2015 | 48,000.00 |
| Mar 31, 2015 | -77,000.00 |
| Mar 31, 2015 | -77,000.00 |
| Dec 31, 2014 | -249,000.00 |
| Dec 31, 2014 | -249,000.00 |
| Sep 30, 2014 | 128,000.00 |
| Sep 30, 2014 | 128,000.00 |
| Jun 30, 2014 | 55,000.00 |
| Jun 30, 2014 | 55,000.00 |
| Mar 31, 2014 | 30,000.00 |
| Mar 31, 2014 | 30,000.00 |